Accéder au contenu
Merck

Atrial fibrillation promotion with long-term repetitive obstructive sleep apnea in a rat model.

Journal of the American College of Cardiology (2014-12-03)
Yu-Ki Iwasaki, Takeshi Kato, Feng Xiong, Yan-Fen Shi, Patrice Naud, Ange Maguy, Kyoichi Mizuno, Jean-Claude Tardif, Philippe Comtois, Stanley Nattel
RÉSUMÉ

Obstructive sleep apnea (OSA) importantly contributes to the occurrence of atrial fibrillation (AF) in humans, but the mechanisms are poorly understood. Experimental research has provided insights into AF promotion by acute OSA episodes. However, patients with OSA usually have frequent nocturnal episodes for some time before manifesting AF. The goal of this study was to test the hypothesis that repetitive OSA causes cardiac remodeling that predisposes to AF. We mimicked OSA by using a mechanical ventilator and closing the airway at end-expiration with a 3-way stopcock (OSA rats). Matched control groups included rats with the ventilator stopped but airway left open (open airway rats) and continuously ventilated rats (sham rats). OSA rats were exposed to 20 consecutive 2-min cycles of 40 s of apnea/80 s of ventilation per day, 5 days per week for 4 weeks. OSA significantly increased the duration of AF from (median [interquartile range]) 2.6 s [1.9 s to 8.9 s] (shams) and 16 s [1.8 s to 93 s] (open airway) to 49s [34 s to 444 s]. AF inducibility increased to 56% (9 of 16) of OSA rats; this is up from 15% (2 of 13) and 13% (2 of 15) in open airway and sham rats, respectively (p < 0.05). OSA rats exhibited substantial atrial conduction slowing on optical mapping, along with connexin-43 down-regulation on both quantitative immunofluorescence (expression reduced by 58% vs sham rats) and Western blot (reduced by 38%), as well as increased atrial fibrous tissue content (by 71%). OSA also caused left ventricular hypertrophy, dilation, and diastolic dysfunction and enhanced AF inducibility during superimposed acute OSA episodes to 82.4% of rats. Chronically repeated OSA episodes cause AF-promoting cardiac remodeling, with conduction abnormalities related to connexin dysregulation and fibrosis playing a prominent role. This novel animal model provides mechanistic insights into an important clinical problem and may be useful for further exploration of underlying mechanisms and therapeutic approaches.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Phosphate de potassium monobasic, ACS reagent, ≥99.0%
Sigma-Aldrich
Chlorure de sodium, for molecular biology, DNase, RNase, and protease, none detected, ≥99% (titration)
Sigma-Aldrich
Phosphate de potassium monobasic, powder, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99.0%
Sigma-Aldrich
Chlorure de sodium solution, 5 M in H2O, BioReagent, for molecular biology, suitable for cell culture
Sigma-Aldrich
Chlorure de sodium solution, 0.9% in water, BioXtra, suitable for cell culture
Sigma-Aldrich
Chlorure de sodium, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99%
Sigma-Aldrich
Phosphate de potassium monobasic, buffer substance, anhydrous, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., 99.5-100.5%
Sigma-Aldrich
Chlorure de sodium, BioXtra, ≥99.5% (AT)
SAFC
Chlorure de sodium solution, 5 M
Sigma-Aldrich
Phosphate de potassium monobasic, for molecular biology, ≥98.0%
Sigma-Aldrich
Chlorure de sodium solution, BioUltra, for molecular biology, ~5 M in H2O
Sigma-Aldrich
Chlorure de sodium, BioUltra, for molecular biology, ≥99.5% (AT)
Sigma-Aldrich
Phosphate de potassium monobasic, meets analytical specification of Ph. Eur., NF, E340, anhydrous, 98-100.5% (calc. to the dried substance)
Sigma-Aldrich
Phosphate de potassium monobasic, ReagentPlus®
Sigma-Aldrich
Phosphate de potassium monobasic, BioUltra, for molecular biology, anhydrous, ≥99.5% (T)
Supelco
Chlorure de sodium, reference material for titrimetry, certified by BAM, >99.5%
Sigma-Aldrich
Phosphate de potassium monobasic, 99.99% trace metals basis
Sigma-Aldrich
Sodium chloride-35Cl, 99 atom % 35Cl
Sigma-Aldrich
Chlorure de sodium solution, 0.85%
Sigma-Aldrich
Phosphate de potassium monobasic, tested according to Ph. Eur., anhydrous
Supelco
Phosphate de potassium monobasic, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Phosphate de potassium monobasic, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Chlorure de sodium, tested according to Ph. Eur.